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Cervical carcinomaSummary We evaluated the reliability of a novel multiplex ligation-dependent probe amplification
(MLPA) assay in detecting integration of human papillomavirus (HPV) based on the viral E2/E6 copy
number ratio in formalin-fixed and paraffin-embedded cervical lesions. The MLPA results were
compared with those of amplification of papillomavirus oncogene transcripts for RNA, detection of
integrated papillomavirus sequences for DNA, and HPV fluorescence in situ hybridization (FISH).
DNA was isolated from 41 formalin-fixed and paraffin-embedded HPV-positive cervical lesions
(cervical intraepithelial neoplasia grade 3 lesions, squamous cell carcinomas, and adenocarcinomas) for
MLPA analysis. From 13 matching frozen samples, DNA and RNA were isolated for the detection of
integrated papillomavirus sequences and/or the amplification of papillomavirus oncogene transcripts,
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2411HPV MLPA assayintegration in 12 of these 13 cases, and episomal copies also were detected in 7 cases. In 20 of the 24
cases with exclusive viral integration or episomal viral copies as detected by FISH, MLPA confirmed
the physical status of the virus. In the cases classified as mixed by FISH, the presence of excess
episomal copies complicated the recognition of viral integration by MLPA. Furthermore, the feasibility
of detecting gain of the telomerase genes with the HPV MLPA assay was evaluated. The MLPA
confirmed the FISH data in 12 of 13 cases in which the status of copy number gain for telomerase RNA
component was known. In conclusion, the HPV MLPA assay can be performed on routinely processed
cervical lesions for the detection of viral load and HPV integration.
© 2013 Elsevier Inc. All rights reserved.1. Introduction FISH pattern, respectively. However, the interpretation ofUterine cervical cancer is the second most common can-
cer in women worldwide, with approximately 500000 new
cases and 275000 deaths estimated in 2002 [1]. Human
papillomavirus (HPV) plays a causal role in the development
of this disease [2] and has been identified in most cervical
carcinomas [3]. In addition to cervical carcinoma, HPV has
been identified in several other sites, including tonsillar [4],
anal [5], and penile [6] carcinomas. HPV types 16 and 18 are
the most prevalent oncogenic types in cervical carcinoma
and are responsible for more than 70% of cases [7,8].
However, although HPV infection is an indispensable
factor, it is not sufficient to cause cancer [9]. For HPV16, a
high viral load is described as an indicator of persistent
infection, which, in turn, is associated with progression to
carcinoma. Furthermore, integration of the HPV genome into
the host genome is associated with progression to carcinoma
[10]. Typically, part of the E2 gene and sometimes also the
E1 or L1 genes [11] are lost on integration into the host
genome, whereas E6 and E7 almost always are retained.
Several studies that have analyzed themost frequently deleted
region were not able to identify 1 general minimum region
that is always deleted [12,13].
One way to analyze integration is by the detection of viral
cellular fusion transcripts, as is done with the amplification
of papillomavirus oncogene transcripts (APOT) assay [14].
Because the presence of human sequences in the transcript is
used as the indicator of integration, the APOT assay is able to
detect all actively transcribed cases with integration inde-
pendent of the location of the viral deletion. Unfortunately,
the need for RNA makes it undesirable to use this assay for
analysis of routinely processed formalin-fixed and paraffin-
embedded (FFPE) samples, as it is difficult to retrieve good-
quality RNA from this type of sample [15].
The detection of integrated papillomavirus sequences
(DIPS) assay is a DNA assay that also uses the fusion between
viral and human sequences for the detection of integration
[16]. However, most amplified products have fragments larger
than 300 base pairs, making it difficult to apply this assay to
FFPE tissue samples. Alternative assays that can be used to
determine integration in paraffin-embedded tissue are de-
scribed, but their sensitivity in detecting integration is limited.
Fluorescence in situ hybridization (FISH) distinguishes
episomal from integrated HPV based on a diffuse or punctatethese patterns is subjective, and there can be both interobserver
and intraobserver differences. Other integration assays use the
predominant deletion of the E2 gene for the analysis of viral
integration through amplification or lack of amplification of an
E2 fragment [17-19], but this assay will not detect integrated
HPV in the presence of episomal copies. On the other hand, by
determining the copy number ratio betweenE6, which is never
deleted, and E2, integration is measured even in a background
of episomal copies based on the relative loss of E2 compared
with E6 [18]. Although the interpretation of these results is
more objective, the E2 amplification usually focuses on a
specific region within the E2 gene, and integration as a result
of deletions outside this region will be missed.
Chromosomal aberrations also correlate with progression
to cancer. These changes can be analyzed by FISH and by
quantitative polymerase chain reaction (PCR) and array
comparative genomic hybridization. However, the latter 2
are difficult to apply to FFPE tissue because of the presence
of significant numbers of normal cells in each sample.
Furthermore, high-quality DNA is needed to perform array
comparative genomic hybridization, and this is difficult to
obtain from paraffin-embedded material.
Recently, we developed a multiplex ligation-dependent
probe amplification (MLPA) assay to detect HPV16/18
simultaneously and to quantify viral load, viral integration,
and gain of the telomerase genes. The MLPA is a molecular
technique initially developed by Schouten et al [20] for the
quantification of as many as 40 genomic targets. For each
target, a pair of probes is designed, each of which contains a
universal PCR primer sequence and a sequence complemen-
tary to the target. When the probes hybridize immediately
adjacent to each other, they can be ligated and subsequently
amplified using universal primers. Because one of the primers
is labeled with a fluorescent dye, the amplified products can
be seen using capillary electrophoresis. Furthermore, the
products can be discerned based on length because of the
variable stuffer sequences [21]. We modified the assay such
that a simultaneous quantification of both human and viral
targets is possible. The HPV MLPA assay was tested on
model systems and on fresh frozen samples of normal cervix,
cervical intraepithelial neoplasia (CIN), and cervical cancer
as well as cytologic samples [22].
The aim of this study was to determine whether the assay
also is applicable to simultaneous analysis of viral load and
2412 W. Theelen et al.integration and gain of the telomerase genes in FFPE tissue
samples. For this study, the MLPA assay was initially per-
formed on a series of FISH samples verified for the physical
status of the virus [23]. The status of 3q copy number gain
was known for several of these cases. In a second series of
FFPE tissue samples, the APOT and DIPS assays had con-
firmed viral integration in the matching fresh frozen samples
[24]. In addition, FISH was performed on this latter series to
confirm the MLPA or APOT results or both.2. Materials and methods
2.1. Materials
FFPE tissue sections from 33 invasive carcinomas (24
squamous cell and 9 adenocarcinomas) and 8 high-grade
squamous intraepithelial lesions were selected for this study
(Tables 1 and 2). For 13 cases, matching paraffin-embedded
and fresh frozen tissue was available (series A). For these
cases, paraffin-embedded sections were used for FISH anal-
ysis, andDNAwas isolated from small parts of these sections,
representing both normal and tumor tissue, through micro-
dissection. Microdissection of 4-μm sections was performed
under an inverted microscope using the edge of a 150-μm-
thick coverslip, guided by a p16-immunostained parallel
section. The p16 immunostaining as a surrogate marker for
HPV infection was performed as previously described [25].
The estimated proportion of tumor cells exceeded 70%. For
10 of these 13 cases, 2 or 3 sections of the same lesion were
available. The matching fresh frozen tissue was used for the
isolation of both RNA and DNA for APOT and DIPS
analysis, respectively. For the 28 remaining cases (series B),
only paraffin-embedded tissue or FFPE sections were avail-Table 1 Summary of APOT, DIPS, FISH, and MLPA results in seri
Case APOT DIPS FISH
HPV type Physical status Viral disruption site Physical s
1 16 Int 2498 Int
2 18 Int 2241 Inconcl
3 16; 18 Int 2048 Inconcl
4 18 Int 2343 Inconcl
5 18 Int 2946 Int
6 16 Int 3438 Int
7 16 Int N3959 Int
8 18 Int 2466 Int
9 16 Int – Inconcl
10 16 Mix 1654 Int
11 16 Mix 1200 Int
12 18 Mix N2438 Inconcl
13 18 Mix 1733 Int
NOTE. For this series, microdissected tissue sections were used for DNA isolat
Abbreviations: AdCa, adenocarcinoma; Epi, episomal; Inconcl, inconclusive; In
SCC, squamous cell carcinoma.
a Viral load is reported as the copy number per genome.able. For these as well as for 7 normal cervical tissues used as
reference, DNA was isolated from tissue microdissected as
described (series A) or from three 10-μm whole tissue sec-
tions without microdissection (series B and reference
samples) using the QIAamp DNA Mini kit (Qiagen, Hilden,
Germany) according to the manufacturer's instructions.
2.2. Multiplex ligation-dependent probe
amplification assay
The MLPA assay was performed as described [19] using
reference samples containing episomal HPV16 or 18 with a
viral load of 2 copies per cell in a background of normal
human DNA in each experiment to correct for experimental
variability. Peak height data were exported to Excel files for
calculation of ratios and analyzed. The HPV positivity was
determined based on the presence of both E6 and E7 peaks.
The E6 and E7 loads were estimated by determining the
signal intensity ratio between E6 or E7 and 7 human targets,
that is, β-globin (2×), MutS homolog 2, telomerase reverse
transcriptase (TERT) (2×), and telomerase RNA component
(TERC) (2×). The average load of E6 and E7 was multiplied
by 2 to obtain the viral load in a diploid cell. For the detection
of the physical status, 2 E2 probes (E2.1 and E2.2) per HPV
type were applied [19], which target the sequences most
frequently deleted on integration into the human genome. The
ratios for each sample were compared with the ratios for the
reference samples containing episomal HPV16 or HPV18 to
determine gain of TERT and TERC as well as the percent-
age of integration. For the 13 cervical cancer samples with
a matching (microdissected) normal sample, the latter was
used as the reference to determine gain of TERT and TERC.
Because of the variability within the measurements, inte-
gration of less than 30% of HPV copies was classified ases A
MLPA Histologic
classificationtatus HPV type Viral load a Physical status
16 1.6 Int SCC
18 1.1 Int SCC
18 1.3 Int SCC
18 0.6 Int SCC
18 2.1 Int AdCa
16 0.8 Mix SCC
16 30.9 Mix SCC
18 5 Mix AdCa
16 1 Epi SCC
16 32.5 Mix SCC
16 30.9 Mix SCC
18 0.9 Mix AdCa
18 12.2 Mix AdCa
ion as described in the “Materials and methods” section.
t, integration; Mix, mixed combined integrated and episomal viral copies;
Table 2 Summary of the HPV-FISH and MLPA results in series B
Case HPV type FISH physical status MLPA Histologic
classificationViral load HPV16 Viral load HPV 18 Physical status High-risk classification
1 18 Int 0.3 ± 0.1 Int + AdCa
2 16; 18 Int 2.2 ± 0.6 0.2 ± 0.1 Mix; Int + SCC
3 16; 18 Int 0.2 ± 0.1 0.2 ± 0.1 Mix; Mix + AdCa
4 16 Int 9.0 ± 1.6 Mix + SCC
5 18 Int 2.0 ± 0.8 Mix + CIN3
6 18 Int 1.8 ± 0.8 Mix + CIN3
7 18 Int 0.2 ± 0.1 Mix + AdCa
8 16; 18 Int 0.1 ± 0.1 1.5 ± 0.4 Epi; Mix + CIN3
9 16 Int 9.9 ± 1.0 Epi − AdCa
10 16 Int 5.5 ± 0.6 Epi − SCC
11 16 Int 4.5 ± 0.6 Epi − SCC
12 16 Int 1.3 ± 0.8 Epi − CIN3
13 16; 18 Mix 5.7 ± 0.5 b0.05 Epi; Epi − CIN3
14 16; 18 Mix 207.3 ± 63.6 0.1 ± 0.1 Epi; Epi + SCC
15 16; 18 Mix 4.4 ± 1.2 0.2 ± 0.1 Epi; Epi − SCC
16 16; 18 Mix 71.9 ± 22.1 0.5 ± 0.2 Epi; Epi + SCC
17 16; 18 Mix 111.5 ± 31.0 b0.05 Epi; Epi + SCC
18 16 Mix 47.9 ± 3.6 Epi + CIN3
19 16 Mix 63.9 ± 0.9 Epi + AdCa
20 16 Mix 4.5 ± 1.8 Epi − SCC
21 16 Mix 40.0 ± 7.8 Epi + SCC
22 16 Mix 196.9 ± 28.5 Epi + SCC
23 16; 18 Epi 183.8 ± 60.0 0.1 ± 0.1 Epi; Epi + SCC
24 16 Epi 2.7 ± 0.8 Epi − CIN3
25 16 Epi 25.7 ± 3.3 Epi + CIN3
26 16 Epi 20.8 ± 1.0 Epi − SCC
27 16 Inconcl 0.1 ± 0.1 Epi − SCC
28 16; 18 Inconcl 1.7 ± 0.5 b0.05 Mix; Inconcl + SCC
NOTE. For this series, whole tissue sections were used for DNA isolation, as described in the “Materials and methods” section.
Abbreviations: CIN3, cervical intraepithelial neoplasia grade 3; Epi, episomal; Inconcl, inconclusive; Int, integration; Mix, mixed combined integrated and
episomal viral copies; high-risk classification, integration or mixed HPV status and/or viral load greater than 25 copies per genome; viral load, mean copy
number per genome ± SD.
2413HPV MLPA assay(predominantly) episomal; between 30% and 95% of in-
tegrated virus was classified as mixed (ie, episomal and
integrated) HPV, and greater than 95% of integrated virus, as
integrated HPV.
All whole tissue sampleswere analyzed in at least duplicate.
The microdissected samples could be analyzed only once.
2.3. Fluorescence in situ hybridization
The FISH analysis was performed using digoxigenin
(Dig)–labeled HPV16 and HPV18 probes (PanPath, Uden,
TheNetherlands) in themild and harsh pretreatment protocols
[26]. The probes were detected using the tyramide signal
amplification procedure as previously described for single-
target hybridization using rhodamine-labeled tyramide [27].
In short, the Dig-labeled probe was detected by peroxidase-
conjugated sheep antidigoxigenin Fab fragments (SHaDIG,
1:100; Roche Molecular Chemicals, Basel, Switzerland) or
first mouse antidigoxigenin (MaDig, 1:2000; Sigma Chem-
ical Co, St Louis, MO), then a peroxidase-conjugated rabbit
antimouse (RaM, 1:100; DAKO A/S Glostrup, Denmark),and finally a peroxidase-conjugated swine antirabbit (SwaR,
1:100; DAKO) all for 30-minute incubations at 37°C and
washed in phosphate-buffered saline (PBS)/0.05% Tween-
20. Thereafter, the tyramide signal amplification reaction was
carried out under a coverslip by applying 50 μL (1:500
diluted from a 1mg/mL stock solution in ethanol) rhodamine-
labeled tyramide in PBS containing 0.1 M imidazole, pH 7.6,
and 0.001% H2O2 for 10 minutes at 37°C. The slides were
washed in PBS containing 0.05% Tween-20 (Janssen
Chimica, Beerse, Belgium), dehydrated in an ascending
ethanol series and mounted in Vectashield (Vector Labora-
tories, Burlingame, CA) containing 4′,6-diamidino-2-pheny-
lindole (0.5 ng/μL; Sigma Chemical Co).
Images were recorded with the Metasystems Image Pro
System (black and white CCD camera; Sandhausen, Ger-
many) mounted on a Leica DM-RE fluorescence microscope
equipped with tetramethylrhodamine isothiocyanate
(TRITC) and 4′,6-diamidino-2-phenylindole single bandpass
filters for single-color analysis.
Controls included HPV16 and HPV18 hybridization on
tissue sections of FFPE HPV-positive cell lines (SiHa,
2414 W. Theelen et al.CaSki, and HeLa). Signal morphology was categorized as
follows. When nuclei were completely and homogeneously
stained, the signal was classified as episomal, whereas dis-
crete nuclear signals (1-3 per nucleus) in a clean background
were classified as integrated, in line with the criteria of
Cooper et al [28].
The FISH patterns were classified by A. H. and A. H. N. H.
Discordant interpretations were resolved by review of the
samples until consensus was reached. Both A. H. and
A. H. N. H. were blinded to the outcomes of the MLPA,
APOT, and DIPS assays. The histologic diagnosis was
known to both.
2.4. Amplification of papillomavirus
oncogene transcripts
Total RNA was reverse transcriptase transcribed, and the
resulting HPV oncogene transcripts were amplified as
described [14], with minor modifications. Total RNA (500-
1000 ng) was transcribed using 100 U of MMLV reverse
transcriptase Superscript II (Invitrogen Life Technologies,
Carlsbad, CA) and an adaptor-linked oligo(dT) primer [29].
Subsequent seminested PCR was performed using HPV E7-
specific forward primers and reverse adaptor primer and an
oligo(dT) primer, respectively.
2.5. Detection of integrated papillomavirus sequences
The DIPS assay was performed as described previously
[16], with minor modifications. Digestion of 1.2 μg of
genomic DNA by restriction endonuclease Sau3AI was
followed by ligation of an enzyme-specific double-stranded
adaptor containing a double- and a single-stranded part
(“vectorette feature”). After the first linear PCR using distinct
viral primers for HPV16 and HPV18, a second PCR step
using a nested viral primer and an adaptor primer 1, which is
complementary to the missing strand of the single-stranded
part of the adaptor, was performed.
2.6. Sequence analysis of viral cellular junctions
obtained by APOT and DIPS
The PCR products of interest were excised from the gel
and extracted using the Qiagen Gel Extraction Kit (Qiagen,
Hilden, Germany). Sequencing reactions were performed
using the Big-Dye terminator DNA-sequencing kit (Perkin
Elmer, Boston, MA) and an ABI Prism 310 Genetic Analyser
(Applied Biosystems, Foster City, CA). Sequencing results
were analyzed using the BLASTN program provided by the
US National Cancer Institute.3. Results
Viral type, load, and integration as well as gain of the
telomerase genes have been shown to be useful in determiningprogression to cervical cancer. This has been demonstrated
using the HPV MLPA assay on fresh frozen tissue samples as
well as by other groups of investigators using other assays,
including APOT, DIPS, FISH, and quantitative PCR assays
measuringE2/E6. We now demonstrate the feasibility of using
the HPV MLPA assay for the analysis of FFPE material.
Tables 1 and 2 summarize the results of MLPA analysis
compared with the APOT, DIPS, and FISH data. These assays
have been validated by comparison with other tests and are
regarded as standards for the detection of viral integration.
3.1. Multiplex ligation-dependent probe
amplification HPV typing and viral load
In the 13 FFPE samples with matching fresh frozen tissue,
the MLPA assay identified 7 cases as HPV18 positive and 6
cases as HPV16 positive (see Table 1). No double infections
with HPV16 and HPV18 were found. The matched fresh
frozen tissue samples, of which some have been previously
reported [24], showed HPV18 in 6 cases, HPV16 in 6 cases,
and coinfection with HPV16 and HPV18 in 1 case. Typical
examples of MLPA capillary electrophoresis peak profiles
are shown in Fig. 1A and B, which illustrate the profiles for
normal tissue and an HPV18-positive tumor (case 3). The
biologic reproducibility of the MLPA assay to determine
viral load was analyzed in tumor tissue fragments from 10
patients and is illustrated in Fig. 2A for the HPV16- and
HPV18-positive patients. In 8 of these 10 patients, the
variation of the viral load within the different tissue blocks
from the same tumor was relatively low (within a factor of 2).
For series B, the samples were not microdissected, and
therefore, the viral load may be influenced by contamination
with stromal cells orHPV-negative normal epithelial cells. This
is particularly obvious in cases 1, 3, 7, and 27 (see Table 2),
which showed on average less than 1HPV copy per genome. In
series B, the HPV MLPA assay detected HPV16 in 14 cases,
HPV18 in 4 cases, and double infection in 10 cases.
3.2. Comparison of the MLPA assay with APOT and
DIPS methods to detect integration
Using the APOT assay, integration of the virus into the
genome was found in all cases. In 4 cases, RNA transcripts
from episomal HPV copies also were detected. A deletion of
E2 relative to E6 was detected in all HPV18- and 5 of the 6
HPV16-positive cases with the MLPA assay. In 7 of these
cases, episomal copies were also seen (mixed HPV). In 1
case, the E2/E6 ratio indicated exclusively episomal viral
copies. Fig. 3A to C shows examples of MLPA peak profiles
of tumors with episomal and integrated viral copies. To
identify the viral disruption sites, DIPS analysis was used to
amplify the downstream fusion region between viral and
cellular DNA. Sequence analysis of the DIPS amplification
products showed the 3′ disruption site in the HPV genome to
be different in all samples, ranging from position 1200 in the
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Fig. 1 Examples of MLPA capillary electrophoresis peak profiles
from DNA isolated from normal (A) and tumor tissue (B).
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) in multiple samples from the case series A. Abbreviations: case
nr, case number; R, reference sample.
2415HPV MLPA assayHPV E1 gene to approximately 4000 in the HPV E5 gene
(see Table 1). The difference in the E2.1/E6 and E2.2/E6
ratio measured with the MLPA assay was low in the various
tumor biopsies from the same patients (see Fig. 2B and C). In
case 6, a significant difference in the E2.1/E6 and E2.2/E6
ratios was found in the 2 biopsies. This resulted in the
classification of 1 sample as integrated HPV and the other as
both episomal and integrated HPV (mixed). In case 2, a
difference in viral load for 1 of the 3 biopsies was measured,
but not for the E2.1/E6 and E2.2/E6 ratios.
3.3. Comparison of the MLPA assay with FISH
method to detect integration
Both series were analyzed by FISH. In FFPE sections, HPV
integration manifests as punctate nuclear signals (see Fig. 3E).
An example of episomal copies is depicted in Fig. 3D
(including replication of the virus). In series A, viral
integration was detected in 8 of 13 cases. In 5 cases, the
FISH pattern was inconclusive for identifying viral integration
or episomal copies, as no clear FISH pattern could be recog-
nized. In all cases with an inconclusive pattern, we detected a
minute viral load, ranging from 0.6 to 1.1 copies per genome.
Because of the small number of FFPE tissue sections available,
we could not repeat the hybridization experiments to improve
immunochemical detection sensitivity. In this series, MLPA
confirmed APOT and DIPS as well as FISH classification in 9
cases. Discrepancies between the assayswere found in 4 cases,
one of which showed concordance between the DIPS and the
MLPA assay, with both unable to detect any viral integration.
The other cases showed viral integration by all 3 of the
reference methods but not by MLPA.
Table 2 summarizes the HPV-FISH and MLPA analysis
of series B; in these cases, no APOT and DIPS data wereavailable. The FISH method identified viral integration in 22
cases: the MLPA confirmed integration in 8 of these. In the
14 discordant cases, MLPA classified the samples as con-
taining exclusively episomal viral copies. The 4 cases clas-
sified as episomal by FISH (no. 23-26) were also classified
as episomal by MLPA. Three cases were classified as
inconclusive by FISH: the MLPA detected a low viral load
in these samples.
3.4. Ability of the MLPA assay to detect gain of
TERC and TERT in FFPE material
The first MLPA experiments on FFPE material showed an
altered peak profile for the human DNA targets compared
with the profiles seen in the fresh frozen clinical samples.
The capillary electrophoresis peak profiles for DNA isolatedA
B
C
F
m
(C
A       HPV 16  episomal
B       HPV 16  integrated
C       HPV 18  integrated
D E
TERTa 16E2.1 TERTc16E7 16E2.2 MSH2 16E6
TERTa 16E2.1 TERTc16E7 16E2.2 MSH2 16E6
18E2.2 TERTc TERCa 18E6 MSH2 18E718E2.1
Fig. 3 A-C, Examples of MLPA capillary electrophoresis peak
profiles for episomal (A, case 9), integrated HPV16 (B, case 1), and
integrated HPV18 (C, case 3) in FFPE carcinomas from sample
series A. Note the arrowheads indicating the absence of detectable
E2 signals in B and C. D and E, Examples of FISH patterns seen for
episomal (D) and integrated HPV (E), case 25 from series B and
case 10 from series A, respectively.
ig. 4 Examples of MLPA capillary electrophoresis peak pro-
les for DNA isolated from normal fresh frozen (A) and FFPE
) material.
Table 3 Gain of TERC by FISH and MLPA in selected
samples from series B
Case FISH TERC
gain
MLPA TERC
gain
Histologic
classification
1 − − AdCa
2 − − SCC
7 − − AdCa
8 − − CIN3
10 − − SCC
11 − + SCC
15 − − SCC
16 + + SCC
17 + + SCC
18 − − CIN3
20 − − SCC
22 + + SCC
28 − − SCC
Abbreviations: AdCa, adenocarcinoma; CIN3, cervical intraepithelial
neoplasia grade 3; FISH, fluorescence in situ hybridization; MLPA,
multiplex ligation-dependent probe amplification; SCC, squamous-cell
carcinoma; TERC, telomerase RNA component.
2416 W. Theelen et al.from fresh and FFPE material are illustrated in Fig. 4A and
B. The low intensity of β-globin-a, β-globin-b, and MutS
homolog 2 compared with the TERT and TERC peaks is
clear. As a result, the signal intensity ratios for the TERT and
TERC genes are different for these samples. Seven FFPE
normal cervical samples showed average signal intensity
ratios ± SD of 3.20 ± 1.85, 10.67 ± 4.04, 33.23 ± 16.23, and
26.50 ± 12.26 for TERTa, TERTc, TERCa, and TERCb,
respectively, whereas the 7 previously described fresh frozen
normal cervical samples showed average signal intensity
ratios of 0.60 ± 0.18, 3.40 ± 1.14, 2.39 ± 0.67, and 1.53 ±
0.42 for TERTa, TERTc, TERCa, and TERCb, respectively
[19]. These paraffin-embedded normal cervical samples
were used to determine the reference threshold of value for
the measurement of gain for TERT and TERC. Table 3
summarizes the TERC gains as detected by FISH and
MLPA: 3 to 5 measurements were needed to measure the
peak ratio between TERCa/b and the human references
accurately. In these samples, the MLPA confirmed gain or
absence of gain of TERC as detected by FISH in 12 of the 13
cases. In 1 case, the MLPA detected a gain, whereas FISH
showed no gain. The utility of the MLPA (in its presentF
fi
(Bform) to detect gain of TERC and TERT routinely is limited
by reproducibility issues.4. Discussion
This study demonstrates that the HPV MLPA assay can
be applied to FFPE material for the detection of viral load
and viral integration, whereas detection of gain of telome-
rase-related genes requires further technical improvements.
Application of this assay to routinely processed material is a
2417HPV MLPA assayprerequisite for studies of the biology of HPV and for the
diagnosis of these features of cervical lesions.
The main issue in the detection of viral integration is the
variability in the outcome of the procedures used to assess
the physical status. As described by Pett and Coleman [30],
there are 2 categories of methods to detect viral integration,
each with its own benefits and flaws. On the one hand, some
protocols, including the DIPS assay, quantative polymerase
chain reaction (qPCR), MLPA, and DNA FISH, detect early
viral integration. Thus, these techniques will detect viral
integration even in low-grade lesions. On the other hand,
procedures that rely on the detection of transcriptionally
active integrated virus, such as the APOT assay and RNA
FISH, detect virus incorporated into the host genome at an
advanced stage of carcinogenesis. Each of the assays has its
own limitations. The assays with a high detection rate
(APOT and DIPS) cannot be applied to FFPE tissue, limiting
their use in daily practice. Although FISH can be applied to
both fresh frozen and FFPE tissue, its interpretation is
subjective. The HPV MLPA assay (and other qPCR assays)
can be applied readily to fresh frozen tissue, cytologic
samples, and FFPE material. However, it might not detect
viral integration in the presence of predominantly episomal
copies, as these will increase the E2/E6 ratio. Because of
these problems, several methods were used in this study to
detect viral integration, as no single assay can be considered
the criterion standard.
In series A, for which there was matched frozen tissue,
the analysis of the physical status of the virus using the
MLPA assay correlated well with the physical status, as
determined with the APOT assay. Samples 6, 7, and 8 in
series A showed integration by APOT/DIPS but a mixed
pattern by MLPA. The viral disruption in those samples is at
the end of E2 (see Table 1). Integration was missed in only 1
case: a possible explanation for this is that the deletion is
outside the E2 MLPA target sequences. In this series, all the
techniques, that is, APOT, FISH, and MLPA, detected viral
integration efficiently.
In sample series B, for which only FFPE tissue was
available, the FISH patterns suggested viral integration in 14
cases, whereas the MLPA suggested that only episomal
copies were present. In 4 cases, FISH identified only inte-
grated HPV, whereas the MLPA assay suggested that only
episomal HPV was present. Similar to the discrepancy
between the MLPA and APOT assays, this may be the result
of a deletion outside the E2 target sequences or retention of
E2 perhaps as part of integrated tandem HPVDNA repeats as
is found, for example, in CaSki cells [31]. This was con-
firmed in a previous study, in which the MLPA could not
detect viral integration in CaSki cells [19]. In several sam-
ples, FISH showed a mixed pattern, indicating the presence
of both episomal and integrated HPV, but the integrated virus
was not classified or recognized by the MLPA assay. The
lack of detection of integrated HPV copies in samples where
both integrated and episomal copies are present can be
explained by the cutoff value applied to classify viralintegration. In samples where less than 30% of the virus is
integrated, this integration will not be detected because of
technical issues, as described in the “Materials and methods”
section. Therefore, these samples were classified as (pre-
dominately) episomal. However, the presence of integrated
HPV, as detected by the MLPA assay, was confirmed by
FISH in nearly all cases. In most of these cases, the MLPA
assay also detected the presence of episomal HPV, whereas
FISH detected exclusively integrated HPV. Possible expla-
nations for the apparent absence of episomal copies by FISH
analysis include the presence of a small proportion of epi-
somal copies relative to integrated copies or the loss of
episomal viral copies during FISH pretreatment [26]. Fur-
thermore, it is important to recognize that the FISH pattern
suggests viral integration but does not describe the fraction
of cells that contain integrated virus.
Comparison of the capillary electrophoresis peak profiles
from the normal samples of both FFPE and fresh samples
shows that there are some appreciable differences in signal
intensity. The FFPE normal cervix DNA shows a strong
reduction in the β-globin signals and an increase in TERC
signals compared with the fresh frozen normal lymphocyte
DNA. These differences may be attributable to the use of
different tissues but are most likely the result of the for-
malin fixation and paraffin embedding used to prepare the
cervical samples.
The assessment of the different parameters in this assay
may be influenced by these changes in the capillary electro-
phoresis peak profile, as these parameters are determined
based on signal intensity ratios. The assessment of viral type
and integration is not influenced by these changes because
HPV signal intensities alone are used for this purpose, and
these do not show any appreciable differences. For viral
load, the signal intensity ratio between E6 or E7 and all
human targets is used, and therefore, this change in capillary
electrophoresis peak profile may have an effect. On the
other hand, the reduction in β-globin signal intensity is
counteracted by the increase in TERT and TERC signal
intensity resulting in minor to no changes in signal intensity
ratio for the assessment of viral load.
In conclusion, the HPV MLPA assay can be performed
using routinely processed cervical lesions for the detection of
viral load and HPV integration in a single assay. The ability
to perform multiparametric analysis on routinely obtained
clinical material will allow investigation of the role of these
molecular parameters in HPV-associated carcinogenesis and
further evaluation of their potential diagnostic role.References
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